Tenderwize
Zurück zur Suche

Open-house rebate agreement for Alfacalcidol

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Nov 30, 2027 · 462 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Alfacalcidol, ATC A11CC03

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

52 / 100

Komplexität

58 / 100

Risikofaktoren

The notice requires either handwritten original documents or documents signed with a qualified electronic signature; or...

Only pharmaceutical companies are eligible, and medicines must be authorised and marketable in Germany.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for pharmaceutical products containing Alfacalcidol (ATC A11CC03).
  • Supply of only authorised and marketable medicines in Germany.
Vollständige Zusammenfassung anzeigen

This is an open-house supply arrangement for pharmaceutical products with AOK Rheinland-Pfalz/Saarland for the active substance Alfacalcidol (ATC A11CC03). It is non-exclusive, open to pharmaceutical companies only, with uniform terms and no individual negotiation. The contract period runs from 01.02.2026 to 31.01.2028, with monthly entry possible during the term. No contract value is stated. Submission is not electronic-only: handwritten originals or electronically signed documents by email are allowed, but the notice says electronic submission is otherwise not allowed. Procurement documents appear available via DTVP, but no procurement document text beyond the TED XML notice was provided for analysis.

Risiken

The notice requires either handwritten original documents or documents signed with a qualified electronic signature; or...

Only pharmaceutical companies are eligible, and medicines must be authorised and marketable in Germany.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Medicines must be authorised and marketable in Germany.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • If a product is not listed in Lauer-Taxe at submission time, an AMIce database extract must be provided.

Auftraggeber

Lose (1)

LOT-0001

Open-house rebate agreement for Alfacalcidol

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing Alfacalcidol (ATC A11CC03). The scope excludes medicines on the BfArM list under Section 35(5a) SGB V (children's medicines). Contract terms are uniform for all participants; no individual negotiations. Contract start is earliest 01.02.2026 and contracts may be entered monthly during the 24-month period. The lot information comes from structured data and the XML notice.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Jan 2026 - Jan 2028

Kategorie

Pharmaceutical products

Frist

Deadline Nov 30, 2027

Vergabedetails

Veröffentlichungsdatum
09 Dec 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
817817-2025

Dokumente (1)

Ähnliche Ausschreibungen